<div id="readability-page-1"><p>Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) were down 5.3% during trading on Friday . The stock traded as low as $27.55 and last traded at $27.6350. Approximately 772,530 shares were traded  during mid-day trading, a decline of 15% from the average daily volume of 904,194 shares. The stock had previously closed at $29.17.</p><div><p><span></span><span>Get <strong>Agios Pharmaceuticals</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities research analysts have recently issued reports on the company. Royal Bank Of Canada cut Agios Pharmaceuticals from an &#34;outperform&#34; rating to a &#34;sector perform&#34; rating and decreased their price objective for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. The Goldman Sachs Group cut their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, November 20th. Wall Street Zen cut shares of Agios Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, November 22nd. Leerink Partnrs raised shares of Agios Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, November 20th. Finally, Weiss Ratings  reaffirmed a &#34;sell (d)&#34; rating on shares of Agios Pharmaceuticals in a research note on Monday. One analyst  has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $38.89.</p><p><b>View Our Latest Stock Analysis on AGIO</b></p><h2>Agios Pharmaceuticals Stock Performance</h2><p>The firm has a fifty day moving average of $34.03 and a 200 day moving average of $36.26. The firm has a market capitalization of $1.61 billion, a PE ratio of -3.95 and a beta of 0.87. </p><p>Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The business had revenue of $12.88 million during the quarter, compared to the consensus estimate of $10.49 million. During the same period in the prior year, the firm earned $16.22 earnings per share. The business's quarterly revenue was up 43.3% compared to the same quarter last year.  Research analysts forecast that  Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year. </p><h2>Insider Activity</h2><p>In other news, insider Sarah Gheuens sold 3,302 shares of the company's stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $43.92, for a total value of $145,023.84. Following the sale, the insider owned 61,727 shares in the company, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 3,902 shares of company stock valued at $170,754 in the last three months. 4.30% of the stock is currently owned by insiders. </p><h2>Institutional Trading of Agios Pharmaceuticals</h2><p>Several institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP raised its stake in  Agios Pharmaceuticals by 31.4% during the 2nd quarter. Marshall Wace LLP now owns 684,669 shares of the biopharmaceutical company's stock valued at $22,772,000 after acquiring an additional 163,796 shares in the last quarter.  Assenagon Asset Management S.A. acquired a new position in shares of  Agios Pharmaceuticals during the 3rd quarter valued at $2,696,000.  Frazier Life Sciences Management L.P. increased its position in shares of  Agios Pharmaceuticals by 19.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,279,754 shares of the biopharmaceutical company's stock valued at $42,565,000 after purchasing an additional 209,900 shares during the period.  Connor Clark &amp; Lunn Investment Management Ltd. raised its stake in shares of  Agios Pharmaceuticals by 30.7% in the 2nd quarter. Connor Clark &amp; Lunn Investment Management Ltd. now owns 505,225 shares of the biopharmaceutical company's stock worth $16,804,000 after buying an additional 118,702 shares in the last quarter.  Finally, Boothbay Fund Management LLC lifted its holdings in shares of  Agios Pharmaceuticals by 71.1% in the second quarter. Boothbay Fund Management LLC now owns 447,019 shares of the biopharmaceutical company's stock valued at $14,868,000 after buying an additional 185,798 shares during the period. </p><h2>About Agios Pharmaceuticals</h2> (Get Free Report)<p>Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company's scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.  </p><p>Agios's lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.</p><h2>See Also</h2><ul><li>Five stocks we like better than Agios Pharmaceuticals</li><li>With a $7 Valuation, NNVC Could Disrupt the Biotech Space in 2026</li><li>BNZI Posts Record Q3 Revenue – See What’s Driving It.</li><li>Do you know what Amazon is planning for January 1?</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>[How To] Claim Your Pre-IPO Stake In SpaceX!</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Agios Pharmaceuticals Right Now?</h2><p>Before you consider Agios Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.</p><p>While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AGIO

<p>Agios Pharmaceuticals (NASDAQ:AGIO) shares fell 5.3% during trading, with the stock trading as low as $27.55. Analysts have mixed ratings, with some downgrading the stock and others upgrading it. The company reported better-than-expected earnings, but insiders have been selling shares. Institutional investors have adjusted their stakes, with some increasing and others reducing their holdings.</p>

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Should You Sell?